Information  X 
Enter a valid email address

Netscientific PLC Ord 5P (NSCI)

Related News

27-Apr-2020 01:58 PM

NetScientific books annual loss amid higher R&D spend

Healthcare intellectual property investor NetScientific booked a full-year loss as its portfolio companies invested more in R&D. Pre-tax losses for the year through December amounted to £3.6m, compared to losses of £4.1m on-year. Cash at at
22-May-2019 08:22 AM

NetScientific posts annual loss as investment costs weigh

Healthcare IP group NetScientific posted a full-year loss, which it said reflected ongoing investment in its portfolio companies. Pre-tax losses for the year through December amounted to £4.1m, compared to losses of £4.4m on-year. 'Our
05-Jun-2018 09:23 AM

NetScientific to present on 27 June 2018 at the Shares and AJ Bell Spotlight Evening in Manchester

The Shares and AJ Bell Media evening event in Manchester is an opportunity for senior board directors from fast growing listed PLCs to make a presentation about their company and update existing & potential investors on their business plans for 2018.
15-May-2018 09:42 AM

NetScientific to present on 31 May 2018 at the Shares and AJ Bell Spotlight Evening in Edinburgh

Finding investment ideas for your portfolio. If you are a new investor just starting to invest on your own or a well-experienced one, many investors are interested in selecting individual stocks for their own portfolios, but aren't sure where to begi
29-Mar-2018 08:56 AM

NetScientific narrows losses

NetScientific, the transatlantic healthcare IP commercialisation group, narrowed its loss after tax to £9.4 million from £13.1 million in 2017, reflecting the progression of its portfolio companies and an additional reduction in group central
15-Feb-2018 09:35 AM

NetScientific's ProAxsis secures first sale of NEATstik

NetScientific's portfolio company ProAxsis has announced its first sale of NEATstik, the company's point-of-care test for measuring neutrophil elastase, to a research laboratory conducting a respiratory clinical trial for a pharmaceutical compan
04-Jan-2018 07:37 AM

NetScientific completes liver cancer trial in China

NetScientific's portfolio company Glycotest has completed a clinical evaluation of its diagnostic panel to detect Hepatocellular Carcinoma (HCC), the most common form of liver cancer, in China. In a blind evaluation of 149 HCC positive patients and
05-Dec-2017 10:12 AM

NetScientific to present on 14 December 2017 at the Shares and AJ Bell Spotlight Evening in London

If you are looking for some new investment ideas for 2018, then come along the Shares and AJ Bell Investor Evening in London on Thursday 14 December. Directors from London Stock Exchange listed companies will present their latest plans regarding develop
21-Nov-2017 12:30 PM

Broker Forecast - Stifel issues a broker note on Netscientific Plc

Stifel today reaffirms its buy investment rating on Netscientific Plc (LON:NSCI) and set its price target at 95p. Story provided by
03-Nov-2017 02:25 PM

HRS expands use of Wanda

NetScientific, the healthcare IP commercialisation Group, has confirmed that HRS Home Health (HRS) is expanding its use of Wanda to all of its home health patients. It said this move follows a successful trial evaluation involving high-risk, co-morbid Co
02-Nov-2017 09:21 AM

NetScientific portfolio company granted Chinese patent

NetScientific's portfolio company Glycotest has been granted a Chinese patent providing broad protection of the assays in Glycotest's HCC Panel test for early-stage hepatocellular carcinoma (HCC) and pipeline tests for liver fibrosis and other s
01-Nov-2017 02:13 PM

NetScientific portfolio company publishes research in NPJ

NetScientific has announced that its portfolio company, Vortex BioSciences, published "Workflow optimization of whole genome amplification and targeted panel sequencing for CTC mutation detection" in Nature Partner Journals (NPJ) Genomic Medicin
11-Sep-2017 07:08 AM

ProAxsis signs partnership agreement

NetScientific announced an update for its portfolio company, ProAxsis. ProAxsis signed a partnership agreement to develop activity-based immunoassays for two key respiratory proteases, utilising its novel ProteaseTag technology. The unnamed partner is a
10-Jul-2017 01:04 PM

NetScientific confirms details of collaboration agreement between PDS and Merck

NetScientific has announced a new clinical trial collaboration agreement between its portfolio company PDS Biotechnology (PDS), in which it owns a 17.4% stake, and a subsidiary of Merck & Co., Inc. The Company said the agreement will enable PDS to evalua
21-Jun-2017 01:39 PM

All resolutions passed at AGM of NetScientific

NetScientific has confirmed that all resolutions were passed by shareholders at today's Annual General Meeting. At 1:39pm: (LON:NSCI) Netscientific Plc share price was 0p at 49p Story provided by
12-Jun-2017 01:42 PM

NetScientific raises £8.1m

NetScientific has confirmed that the Company has received valid requests for subscriptions in respect of 45,700 Additional Fundraising Shares as part of its recently announced capital raise programme. The Company has therefore raised a total of £8.
26-May-2017 01:05 PM

NetScientific updates on placing

NetScientific has announced the completion of commitments under the Placing and Subscription to raise a total of £8.1m. Commitments have been obtained to subscribe for a total of 14,083,332 Placing Shares and 3,833,330 Subscription Shares from exis
25-May-2017 02:15 PM

NetScientific looks to raise £9.6m

NetScientific has announced a conditional Placing and Subscription to raise approximately £8.1m and a conditional Additional Fundraising to raise up to approximately £1.5m, before expenses. The Company said the net proceeds of the Placing, Su
03-Apr-2017 07:49 AM

NetScientific widens FY pretax loss

NetScientific has widened its FY pretax loss to £12.4m, from a loss of £10.4m, after a year that saw the company focus on delivering individual development milestones within each of its portfolio companies. Most of the FY pretax loss was due
27-Sep-2016 07:38 AM

NetScientific books wider H1 loss

NetScientific (NSCI) has widened its H1 pretax loss to £6.1m, from a year-earlier restated loss of £4.4m. Revenue was £359,243, from £55,000. The company's executive chair, Sir Richard Sykes, commented: "NetScientific h
15-Jun-2016 02:31 PM

NetScientific resolutions passed at AGM

NetScientific has confirmed that all resolutions proposed at today's annual general meeting were passed. At 2:31pm: (LON:NSCI) Netscientific Plc share price was 0p at 80.5p Story provided by
04-Jan-2016 07:11 AM

NSCI says portfolio company WANDA signs contract

Story provided by
09-Sep-2015 01:05 PM

NetScientific appoints Steve Curd as Wanda CEO

NetScientific has appointed Steve Curd as chief executive of its portfolio company, Wanda, and head of the group's Digital Health franchise, of which Wanda is the key asset. Wanda helps healthcare providers improve outpatient care while reducing th
15-Jul-2015 07:36 AM

NSCI says key patent granted for Glucosense's technology

NetScientific announces the award of the first critical European patent covering Glucosense Diagnostics's core technology. Glucosense is developing a fully non-invasive device to measure the real-time blood glucose levels of people living with diab
29-Apr-2015 02:03 PM

NetScientific to host capital markets day

NetScientific will be holding a capital markets day from 10.30 a.m. to 3.00 on 15 May in London to provide an update on the outcome of its strategy review and highlight the achievements and progress of its key portfolio companies. Sir Richard Sykes
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t